Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CBUS
STRONG SELLCibus, Inc. · Healthcare · United States · $138M · Avg Vol: $711K/d
COMPANY DESCRIPTION
Cibus, Inc. develops and commercializes advanced non-GMO and gene-edited plant traits for agricultural applications, focusing on improving crop yields and sustainability. The company leverages its proprietary Rapid Trait Development System (RTDS) platform, allowing precise genetic modifications without introducing foreign DNA. Cibus is a pioneer in sustainable agricultural biotechnology, offering an alternative to traditional GMOs.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.0M | 0.2M | 1.8M | 4.3M | 3.6M | -38.8% | 4.3M | 7.8M | 113.8% |
| EPS | -39.00 | -0.24 | -6.99 | -3.96 | -2.78 | — | -1.74 | — | — |
| Shares | 0.8M | 76.3M | 76.3M | 76.3M | 54.3M | +6887.4% | — | — | — |
| Debt | 17.9M | 13.9M | 24.6M | 36.3M | 33.0M | 16.6% | 276.2M | — | — |
| Equity | 14.1M | 7.2M | 293.5M | 92.2M | 21.8M | 11.5% | — | — | — |
| Op CF | -18.8M | -19.4M | -46.2M | -58.0M | -50.6M | — | -50.3M | — | — |
| Inv CF | 11.2M | -1.5M | 55.1M | -0.8M | -0.6M | — | — | — | — |
| Fin CF | 3.7M | 10.0M | 20.3M | 40.6M | 46.6M | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CBUS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CBUS | Cibus, Inc.(you) | $138M | 11 | STRONG SELL |
| AARD | Aardvark Therapeutics, Inc. | $138M | 10 | STRONG SELL |
| PEPG | PepGen Inc. | $133M | 9 | STRONG SELL |
| CDXS | Codexis, Inc. | $135M | 12 | STRONG SELL |
| CNTB | Connect Biopharma Holdings Limited | $135M | 13 | STRONG SELL |
| KRRO | Korro Bio, Inc. | $153M | 12 | STRONG SELL |
| 0HIY.L | Atara Biotherapeutics, Inc. | $161M | 10 | STRONG SELL |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $157M | 12 | STRONG SELL |
| VANI | Vivani Medical, Inc. | $110M | 11 | STRONG SELL |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | $164M | 9 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%